Study wrapper · #693
Morphofunctional State of the Large Intestine in Rats under Conditions of Restraint Stress and Administration of Peptide ACTH(4-7)-PGP (Semax).
Editor's note
This rat study looked beyond the brain: in a restraint-stress model, intraperitoneal Semax (5 to 450 microg/kg) was associated with lower corticosterone, reduced stress-induced atrophy and inflammatory changes in the colon wall, and shifts in mast-cell activity. The authors attribute the effects to the peptide's broad physiological and pharmacological actions, plausibly including peripheral melanocortin receptors. It is a small preclinical study with histological and hormonal endpoints, adding a gut and peripheral dimension to Semax's mostly-CNS rodent literature. Interesting for breadth of mechanism; low weight for any clinical claim. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
Stress affects the gut, not just the brain. This rat study tested whether Semax could protect the colon during a stressful restraint procedure. Rats received Semax at several doses shortly before being stressed. Stress alone raised the stress hormone corticosterone and caused signs of shrinkage, inflammation and changes in immune cells (mast cells) in the colon wall. Giving Semax lowered corticosterone, eased those tissue changes, and helped the intestinal wall adapt to stress. The researchers suggest these benefits may come from Semax acting both in the brain and directly on receptors in the gut. This is laboratory work in rats that broadens the picture of how Semax acts throughout the body; it does not show a benefit in humans and reports no findings in people.